AVX-001
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- AVX-001
- DrugBank Accession Number
- DB19194
- Background
AVX-001 is under investigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 386.52
Monoisotopic: 386.189121217 - Chemical Formula
- C21H29F3OS
- Synonyms
- 1-((2e,6z,9z,12z,15z)-octadeca-3,6,9,12,15-pentaen-1-thio)-3,3,3-trifluoroacetone
- 2-propanone, 1,1,1-trifluoro-3-((2e,6z,9z,12z,15z)-2,6,9,12,15-octadecapentaenylthio)-
- External IDs
- AKH 217
- AKH-217
- AKH217
- AVX 001
- AVX-001
- AVX001
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G8333V26KK
- CAS number
- 300553-18-8
- InChI Key
- RBPYIYOPSGHFQG-IIFHDYRKSA-N
- InChI
- InChI=1S/C21H29F3OS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26-19-20(25)21(22,23)24/h3-4,6-7,9-10,12-13,16-17H,2,5,8,11,14-15,18-19H2,1H3/b4-3-,7-6-,10-9-,13-12-,17-16+
- IUPAC Name
- SMILES
- CC\C=C/C\C=C/C\C=C/C\C=C/CC\C=C\CSCC(=O)C(F)(F)F
References
- General References
- Not Available
- External Links
- ChemSpider
- 8484948
- ChEMBL
- CHEMBL5095215
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1, 2 Unknown Status Treatment Actinic Keratosis (AK) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 08, 2024 18:40 / Updated at July 10, 2024 02:16